A directory of the major companies, research consortia, and startups driving the neurotechnology and BCI ecosystem.
Developing ultra-high bandwidth brain-machine interfaces (specifically the N1 implant and R1 surgical robot) using flexible polymer threads inserted directly into the cortex.
Building the Connexus Direct Data Interface, utilizing a massive array of penetrating micro-wires for high data-rate recording, aimed at restoring communication for patients with severe motor impairment.
Pioneers of the Utah Array, one of the most widely used and FDA-cleared microelectrode arrays for human cortical recording in research settings.
Developing the Layer 7 Cortical Interface, a highly flexible, high-density microelectrode array that sits on the surface of the brain (ECoG), inserted minimally invasively via a cranial micro-slit.
Creators of the Stentrode, an endovascular brain-computer interface that is delivered through the jugular vein to the motor cortex, eliminating the need for open brain surgery.
A global leader in medical devices, providing standard-of-care Deep Brain Stimulation (DBS) devices for Parkinson's disease, Epilepsy, and other movement disorders.
A primary competitor to Medtronic in the DBS space, innovating with directional steering of current to minimize side effects during stimulation.
Developing non-invasive, helmet-based neuroimaging systems using Time-Domain Functional Near-Infrared Spectroscopy (TD-fNIRS) to quantify brain activity at scale.
Acquired by Meta, focusing on non-invasive electromyography (EMG) wristbands that decode spinal motor neuron signals for seamless AR/VR interaction.
A consortium of neuroscientists, engineers, and clinicians fundamentally responsible for many of the earliest and most successful human BCI clinical trials utilizing intracortical arrays.
An independent, non-profit organization accelerating the development of neurotechnologies to translate research into clinical solutions.
The Implantable Brain-Computer Interface Collaborative Community; a coordinated effort among academia, industry, patients, and regulatory bodies to accelerate the safe development of iBCIs.